StratifAI Partners with MSK iHub Challenge Cohort to Validate Polaris™ with World-Class Clinical Datasets

StratifAI has joined the MSK iHub Challenge Cohort to accelerate validation of its Polaris™ platform. The platform uses AI to transform routine clinical data into novel biomarkers for cancer treatment decisions. Through MSK's resources, StratifAI will further validate Polaris™ on real-world clinical data, advancing toward regulatory approval and guideline inclusion in the EU and US. The collaboration aims to establish pathways for ongoing validation and strengthen Polaris™' utility for oncologists worldwide.

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) announced the presentation of interim data from its Phase 1b/2 clinical trial of ciforadenant for patients with metastatic renal cell cancer (RCC) at the European Society for Medical Oncology (ESMO) Congress 2025. The trial is evaluating ciforadenant, an adenosine A2a receptor inhibitor, in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) as a potential first-line therapy for metastatic RCC.

The interim data presented at ESMO demonstrates that the triplet therapy with ciforadenant, ipilimumab, and nivolumab is feasible and well-tolerated. Key highlights from the presentation include:

- The median age of patients in the trial was 61.5 years, with 82% having a poor or intermediate prognosis by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria.
- The deep response rate was 34%, an improvement over historical data for the combination of ipilimumab and nivolumab alone, though not statistically significant at this point in time.
- The objective response rate (ORR) was 46%, including two complete responses and 21 partial responses.
- The median progression-free survival (PFS) was 11.04 months.

The trial enrolled 50 patients with newly diagnosed or recurrent stage IV clear cell RCC who had not received any prior systemic therapy. Patients received ciforadenant 100 mg oral, twice-daily in combination with ipilimumab and nivolumab. The primary endpoint for the Phase 1b portion was safety and tolerability, while the primary endpoint for the Phase 2 portion was the percent of patients achieving a deep response.

Richard A. Miller, M.D., co-founder, president, and chief executive officer of Corvus, commented, "Despite enrolling patients with more unfavorable disease compared to historical trials, the triplet combination demonstrated activity that compares favorably to historical results with the doublet alone. These data support our view that blocking adenosine signaling with ciforadenant may provide meaningful benefit for RCC patients."

The collaboration with the Kidney Cancer Research Consortium and the ongoing follow-up of the 19 patients who remain on therapy will help determine the potential of this approach. The trial is expected to provide more insights into the long-term efficacy and safety of ciforadenant in combination with ipilimumab and nivolumab.